Monoclonal Antibody

Monoclonal Antibody designates a highly specific antibody produced by identical immune cells cloned from a single parent cell, recognising and binding to one unique epitope on an antigen with exquisite specificity and affinity, representing one of the most successful therapeutic modalities in modern medicine with applications spanning oncology, autoimmune diseases, infectious diseases, and transplant rejection. These engineered proteins leverage the immune system's natural targeting capabilities, combining exceptional specificity with diverse mechanisms of action.

The biopharmaceutical industry has developed over 100 approved monoclonal antibody therapeutics generating hundreds of billions in annual revenue, with blockbuster products including adalimumab, rituximab, trastuzumab, and pembrolizumab demonstrating remarkable clinical efficacy and commercial success. Antibody engineering evolved through generations from early murine antibodies through chimeric and humanised formats to fully human antibodies. Modern innovations include bispecific antibodies, antibody-drug conjugates, and Fc-engineered variants with tailored effector functions. Manufacturing employs mammalian cell culture producing complex glycoproteins requiring extensive purification and characterisation ensuring consistent quality. As antibody engineering advances through computational design, novel formats, and manufacturing improvements, monoclonal antibodies continue expanding therapeutic applications while maintaining a dominant position as the biopharmaceutical industry's most successful product class.